In a graft-versus-host disease (GVHD) model, TGF-β-induced FOXP3 expression could be stabilized, and iTreg suppressor function was enhanced by co-treatment with rapamycin and IL-2/anti-IL-2 antibody complexes [102,103]. This evidence concerns the gene TGFB1 and graft versus host disease.